Meisoindigo
Based on 2 publication(s) in Google Scholar
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.91%
- CAS No.: 97207-47-1
- Formula: C17H12N2O2
- Molecular Weight:276.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-16560
CamptothecinTopo I inhibitor -
HY-N1201
ApigeninCytochrome P450 Inhibitor -
HY-13067
CelastrolAutophagy Inducer -
HY-N0117
IndirubinAnticancer Agent -
HY-B0015
PaclitaxelAntitumor Agent -
HY-N8433
DhurrinCyanogenic Glucoside -
HY-N1881
4',5-DihydroxyflavoneColA Inhibitor -
HY-N10503
NorartocarpetinTyrosinase Inhibitor -
HY-N4127
3'-Demethylnobiletin -
HY-N6894A
Pseudocoptisine chlorideAChE Inhibitor
Publications Citing Use of MedChemExpress (MCE) Meisoindigo
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
6.57 μM
Compound: Mei
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| A549 | IC50 |
57.3 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| COLO 205 | IC50 |
7.55 μM
Compound: Mei
|
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| HCT-116 | IC50 |
15.4 μM
Compound: 2
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| HCT-116 | IC50 |
27 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| HCT-116 | IC50 |
5.36 μM
Compound: Mei
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| HeLa | IC50 |
15.7 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| HL-60 | IC50 |
12.2 μM
Compound: 2
|
Antiproliferative activity against human HL60 cells after 5 days by MTT assay
Antiproliferative activity against human HL60 cells after 5 days by MTT assay
|
[PMID: 19783149] |
| Huh-7 | IC50 |
18.3 μM
Compound: 2
|
Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay
Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| IMR-90 | IC50 |
7.7 μM
Compound: 2
|
Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| K562 | IC50 |
23.3 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human K562 cells after 48 hrs by SRB assay
Cytotoxicity against human K562 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| K562 | IC50 |
6.7 μM
Compound: 2
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| K562 | IC50 |
8.17 μM
Compound: Mei
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| L1210 | IC50 |
167 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against mouse L1210 cells after 48 hrs by SRB assay
Cytotoxicity against mouse L1210 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| LoVo | IC50 |
12.67 μM
Compound: Mei
|
Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| MGC-803 | IC50 |
128 μM
Compound: 6a, MIO, Meisoindigo
|
Cytotoxicity against human MGC803 cells after 48 hrs by SRB assay
Cytotoxicity against human MGC803 cells after 48 hrs by SRB assay
|
[PMID: 25151579] |
| NCI-H358 | IC50 |
>20 μM
Compound: Mei
|
Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| RKO | IC50 |
11.63 μM
Compound: Mei
|
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW13 | IC50 |
12.89 μM
Compound: Mei
|
Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW480 | IC50 |
2.8 μM
Compound: Mei
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW-620 | IC50 |
9.14 μM
Compound: Mei
|
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
In Vitro
Meisoindigo (Dian III; 5-20 μM; for 24?hours) inhibits growth of the AML cell lines[1].
Meisoindigo (10?μM; for 24?hours) induces apoptosis of acute myeloid leukemia[1].
Meisoindigo (5-10?μM; for 24?hours) causes cell-cycle arrest[1].
Meisoindigo (5-10?μM; for 24?hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells[1].
Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HL-60, NB4, U937 leukemic cell lines
-
Concentration:5, 10, 15, 20 μM
-
Incubation Time:For 24 hours
-
Result:Inhibited growth of the AML cell lines in a dose- and time-dependent manner.
-
Cell Line:HL-60 cells
-
Concentration:10 μM
-
Incubation Time:For 24 hours
-
Result:Induced apoptosis of acute myeloid leukemia.
-
Cell Line:HL-60 cells
-
Concentration:5, 10 μM
-
Incubation Time:For 24 hours
-
Result:Caused cell-cycle arrest, with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase, in a dose-dependent manner.
-
Cell Line:HL-60 cells
-
Concentration:5, 10 μM
-
Incubation Time:For 24 hours
-
Result:Increased the cleaved caspase-3 and pro-apoptotic Bak, and decreased Bcl-2 and Bcl-xL levels in HL-60 cells.
In Vivo
Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice, 6-8 weeks old, with HL-60 leukemic cells[1]
-
Dosage:50, 100, 150 mg/kg
-
Administration:IP; daily; for 14 days
-
Result:Had anti-leukemic activity in vivo.
Chemical Information
-
CAS No. 97207-47-1
-
Appearance Solid
-
Molecular Weight 276.29
-
Formula C17H12N2O2
-
Color Grayish brown to reddish brown
-
SMILES
O=C1N(C)C2=C(C=CC=C2)/C1=C3C(NC4=C\3C=CC=C4)=O
-
Synonyms
Dian III; N-Methylisoindigotin; Natura-α
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. [Abstract]2025 Nov 21:10.1158/0008-5472.CAN-24-3753. PMID: 41270153 -
Solvent & Solubility
In Vitro:
DMSO : ≥ 51 mg/mL (184.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee CC, et al. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leuk Lymphoma. 2010 May;51(5):897-905. [Content Brief]
[2]. Yingze Ye, et al. Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway. Front Cell Neurosci. 2019 Dec 16;13:553. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6194 mL | 18.0969 mL | 36.1939 mL | 90.4846 mL |
| 5 mM | 0.7239 mL | 3.6194 mL | 7.2388 mL | 18.0969 mL | |
| 10 mM | 0.3619 mL | 1.8097 mL | 3.6194 mL | 9.0485 mL | |
| 15 mM | 0.2413 mL | 1.2065 mL | 2.4129 mL | 6.0323 mL | |
| 20 mM | 0.1810 mL | 0.9048 mL | 1.8097 mL | 4.5242 mL | |
| 25 mM | 0.1448 mL | 0.7239 mL | 1.4478 mL | 3.6194 mL | |
| 30 mM | 0.1206 mL | 0.6032 mL | 1.2065 mL | 3.0162 mL | |
| 40 mM | 0.0905 mL | 0.4524 mL | 0.9048 mL | 2.2621 mL | |
| 50 mM | 0.0724 mL | 0.3619 mL | 0.7239 mL | 1.8097 mL | |
| 60 mM | 0.0603 mL | 0.3016 mL | 0.6032 mL | 1.5081 mL | |
| 80 mM | 0.0452 mL | 0.2262 mL | 0.4524 mL | 1.1311 mL | |
| 100 mM | 0.0362 mL | 0.1810 mL | 0.3619 mL | 0.9048 mL |
Meisoindigo Related Classifications
HY-13680 Related Classifications
Powered by Bioz